{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Defined by the detection of at least 50% donor derived T-cells (CD3+), as a proportion of the total T-cell population","groups":[{"description":"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.\n\nTRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.\n\nPOST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.\n\nGRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35.","id":"OG000","title":"Treatment (Nonmyeloablative HSCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients receiving haploidentical transplant who had T cell chimerism tested at day +84","reportingStatus":"POSTED","timeFrame":"At day +84 after transplantation","title":"Donor Engraftment (Chimerism)","type":"PRIMARY","unitOfMeasure":"Participants"}